SCHEMBL3767063

SCHEMBL3767063

O=C(Nc1cccc(C(=O)Nc2ccc3ccccc3n2)c1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RHOC P08134 1/20 0.63
RHOA P61586 1/20 0.63
RAB9A P51151 4/20 0.57
NPC1 O15118 3/20 0.57
RAF1 P04049 1/20 0.56
BRAF P15056 1/20 0.56
KCNK3 O14649 2/20 0.56
PTGES O14684 1/20 0.56
P2RX1 P51575 3/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.53
RXFP1 Q9HBX9 1/20 0.52
PTGS1 P23219 1/20 0.51
MEN1 O00255 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51
KCNK9 Q9NPC2 1/20 0.50
MTOR P42345 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775369 0.94 KCNK3 (0.64) RHOCRHOARAB9ANPC1BRAF
SCHEMBL28230040 0.88 NPC1 (0.66) RAB9ANPC1KCNK3P2RX1LMNA
SCHEMBL3764441 0.86 RAB9A (0.78) RAB9ANPC1KCNK3MAPTMEN1
SCHEMBL3779837 0.86 PTGES (0.69) RAB9ANPC1KCNK3PTGESRXFP1
SCHEMBL3771629 0.81 NPC1 (0.66) RAB9ANPC1KCNK3MEN1KMT2A
SCHEMBL3771069 0.81 NPC1 (0.78) RAB9ANPC1KCNK3RXFP1MEN1
SCHEMBL3776712 0.81 RAB9A (0.67) RAB9ANPC1KCNK3MEN1HTT
SCHEMBL3769427 0.81 NPC1 (0.66) RAB9ANPC1MEN1KMT2AMTOR
SCHEMBL3770483 0.81 KMT2A (0.62) RAB9ANPC1PTGESMAPTMEN1
SCHEMBL4433745 0.81 NPC1 (0.73) RAB9ANPC1MAPTPTGS1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324086-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2010-12-23 US claimed
WO-2009103778-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2009-08-27 WO claimed
US-20100324086-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324086-A1 COMPOUNDS AND METHODS IL1B, LITAF, CYP11B1 RHOC 4277/4885RHOA 4089/4885RAB9A 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.